Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Synergy Pharma (SGYP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,441
  • Shares Outstanding, K 248,037
  • Annual Sales, $ 16,820 K
  • Annual Income, $ -224,340 K
  • 60-Month Beta 4.94
  • Price/Sales 0.18
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.59
  • Most Recent Earnings -0.15 on 05/10/18
  • Next Earnings Date 03/07/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +555,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.03 unch
on 03/07/19
0.32 -90.77%
on 02/20/19
-0.29 (-90.63%)
since 02/07/19
3-Month
0.03 unch
on 03/07/19
0.47 -93.68%
on 01/24/19
-0.33 (-91.67%)
since 12/07/18
52-Week
0.03 unch
on 03/07/19
2.23 -98.65%
on 03/08/18
-2.20 (-98.65%)
since 03/07/18

Most Recent Stories

More News
Global Constipation Treatment Drug Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

VRX.TO : 30.80 (-3.33%)
IRWD : 10.96 (-1.08%)
SCMP : 18.05 (+0.28%)
ALBO : 33.93 (+0.53%)
PBH : 29.70 (+1.12%)
SGYP : 0.03 (-52.00%)
Irritable Bowel Syndrome Treatment Market Size, Future Analysis, Demands and Estimated Industry Growth Forecast to 2028

Irritable bowel syndrome (IBS) is a gastrointestinal disorder that affects large intestine, symptom includes abdominal pain, altered bowel habits, increased gas, bloating (distention), cramping, and food...

VRX.TO : 30.80 (-3.33%)
IRWD : 10.96 (-1.08%)
SCMP : 18.05 (+0.28%)
ALPMF : 13.7600 (+5.85%)
NVS : 86.96 (+2.98%)
SGYP : 0.03 (-52.00%)
GSK : 40.17 (+0.45%)
Significant CAGR Growth to Be Achieved by Chronic Idiopathic Constipation Drugs Market by Global Trends, Size, Growth Rate by 2024

The Chronic Idiopathic Constipation Drugs Market report explores the international major industry players in detail, the report presents the company profile, product specifications, capacity, production...

VRX.TO : 30.80 (-3.33%)
BAYRY : 15.1140 (-0.50%)
TBPH : 18.25 (-0.05%)
IRWD : 10.96 (-1.08%)
SCMP : 18.05 (+0.28%)
MRK : 81.39 (+0.46%)
LLY : 116.86 (+0.04%)
RHHBY : 33.9300 (+0.53%)
SGYP : 0.03 (-52.00%)
Chronic Idiopathic Constipation Drugs Market To Grow At Maximum Value With CAGR between 2019 and 2024

Research report comes up with the size of the global for the base year 2019 and the forecast between 2019 and 2024. Market value has been estimated considering the application and regional segments, market...

VRX.TO : 30.80 (-3.33%)
BAYRY : 15.1140 (-0.50%)
TBPH : 18.25 (-0.05%)
IRWD : 10.96 (-1.08%)
SCMP : 18.05 (+0.28%)
MRK : 81.39 (+0.46%)
LLY : 116.86 (+0.04%)
RHHBY : 33.9300 (+0.53%)
SGYP : 0.03 (-52.00%)
Delisting of Securities of Elbit Imaging Ltd., Helios and Matheson Analytics Inc., Synergy Pharmaceuticals, Inc., Kona Grill, Inc., Presbia PLC, Fusion Connect, Inc., And Achaogen, Inc. from The Nasdaq Stock Market

The Nasdaq Stock Market announced today that it will delist the ordinary shares of Elbit Imaging Ltd. Elbit Imaging Ltd.'s stock was suspended on February 11, 2019 and has not traded on Nasdaq since that...

HMNY : 0.0027 (-3.57%)
NDAQ : 90.11 (+0.10%)
EMITF : 0.9500 (+26.67%)
KONA : 0.0950 (-45.65%)
FSNN : 0.0925 (-3.65%)
SGYP : 0.03 (-52.00%)
Know the Growth Factor of Constipation Treatment Drug Market Size 2025: AstraZeneca, Bayer AG, Sanofi, Sucampo Pharmaceuticals, Inc., Takeda

VRX.TO : 30.80 (-3.33%)
BAYRY : 15.1140 (-0.50%)
ABT : 76.86 (+1.63%)
IRWD : 10.96 (-1.08%)
SCMP : 18.05 (+0.28%)
ALBO : 33.93 (+0.53%)
PBH : 29.70 (+1.12%)
SGYP : 0.03 (-52.00%)
FINAL DEADLINE: Bronstein, Gewirtz & Grossman, LLC - UXIN, SGYP & MHLD

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints...

MHLD : 0.62 (+5.08%)
SGYP : 0.03 (-52.00%)
UXIN : 2.26 (+2.73%)
FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Synergy Pharmaceuticals Inc. ("Synergy" or "the Company") (NASDAQ: SGYP) for violations...

SGYP : 0.03 (-52.00%)
DEADLINE FRIDAY REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Synergy Pharmaceuticals Inc. ("Synergy" or "the Company")...

SGYP : 0.03 (-52.00%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SGYP

Pomerantz LLP announces that a class action lawsuit has been filed on behalf of investors in Synergy Pharmaceutical, Inc. ("Synergy" or the "Company") (NASDAQ: SGYP) against certain of the Company's current...

SGYP : 0.03 (-52.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade SGYP with:

Business Summary

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant-...

See More

Key Turning Points

2nd Resistance Point 0.08
1st Resistance Point 0.05
Last Price 0.03
1st Support Level 0.02
2nd Support Level 0.01

See More

52-Week High 2.23
Fibonacci 61.8% 1.39
Fibonacci 50% 1.13
Fibonacci 38.2% 0.87
Last Price 0.03
52-Week Low 0.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar